ANIP Stock Analysis: ANI Pharmaceuticals | NASDAQ

Injectables, Softgel Capsules, Oral Solids, Topicals

Total Rating 46

Safety 76

Buy Signal -1.08

Drug Manufacturers - Specialty & Generic
Industry Rotation: +0.3

Market Cap: 1.69B
Avg Turnover: 30.2M

Risk 3d forecast

Volatility33.1%

VaR 5^th Pctl5.61%

VaR vs Median2.97%

Reward TTM

Sharpe Ratio-0.92

Rel. Str. IBD11

Rel. Str. Peer Group11.2

Character TTM

Beta-0.021

Beta Downside-0.093

Hurst Exponent0.375

Drawdowns 3y

Max DD28.66%

CAGR/Max DD0.18

CAGR/Mean DD0.39

EPS (Earnings per Share)

EPS CAGR: 22.95%
EPS Trend: 60.2%

Last SUE: 0.33
Qual. Beats: 0

Revenue

Rev. CAGR: 34.49%
Rev. Trend: 99.4%

Last SUE: 0.77
Qual. Beats: 0

Warnings

Below Avwap Earnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan +1.8% 20

Feb -4.5% 9

Mar -2.0% 17

Apr -0.9% 5

May -0.1% 7

Jun +5.0% 32

Jul -1.4% 8

Aug -1.8% 11

Sep -4.3% 17

Oct -0.3% 11

Nov +2.8% 14

Dec -3.0% 25

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: ANIP ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is a U.S.-based biopharmaceutical company incorporated in 2001 and headquartered in Baudette, Minnesota. The company develops, manufactures, and markets both branded and generic prescription pharmaceutical products, selling primarily in the United States with some international reach.

Its product portfolio spans multiple dosage forms and therapeutic categories, including injectable generics, softgel capsules, oral solid doses, semi-solids, liquids, topicals, controlled substances, and potent compounds. On the branded side, the company markets specialty products such as Cortrophin gel, ILUVIEN, and YUTIQ, which are typically sold into narrower physician- or hospital-based channels than its generics.

ANI distributes through a diversified channel mix that includes national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. This dual model - high-volume generic manufacturing combined with niche branded specialty drugs - exposes the company to both competitive generic pricing pressure and the higher-margin dynamics typical of branded specialty pharmaceuticals, including longer exclusivity windows and FDA orphan-drug protections on select products.

Headlines to Watch Out For

Cortrophin gel prescriptions drive branded revenue growth
Generic pricing pressure weighs on margins
ILUVIEN and YUTIQ acquisitions expand rare disease portfolio

Piotroski VR-10 (Strict) 8.0

Net Income: 105.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 2.85 > 1.0
NWC/Revenue: 55.38% < 20% (prev 48.94%; Δ 6.43% < -1%)
CFO/TA 0.13 > 3% & CFO 189.5m > Net Income 105.8m
Net Debt (234.6m) to EBITDA (255.8m): 0.92 < 3
Current Ratio: 2.91 > 1.5 & < 3
Outstanding Shares: last quarter (21.9m) vs 12m ago 7.91% < -2%
Gross Margin: 65.23% > 18% (prev 61.06%; Δ 4.17% > 0.5%)
Asset Turnover: 68.97% > 50% (prev 55.65%; Δ 13.32% > 0%)
Interest Coverage Ratio: 6.20 > 6 (EBIT TTM 170.0m / Interest Expense TTM 27.4m)

Altman Z'' 3.95

A: 0.36 (Total Current Assets 825.4m - Total Current Liabilities 283.7m) / Total Assets 1.49b
B: 0.02 (Retained Earnings 31.1m / Total Assets 1.49b)
C: 0.12 (EBIT TTM 170.0m / Avg Total Assets 1.42b)
D: 0.67 (Book Value of Equity 597.2m / Total Liabilities 896.9m)
Altman-Z'' = 3.95 = AA

Beneish M -3.05

DSRI: 0.93 (Receivables 274.5m/225.7m, Revenue 978.4m/747.4m)
GMI: 0.94 (GM 61.06% / 65.23%)
AQI: 0.79 (AQ_t 0.40 / AQ_t-1 0.51)
SGI: 1.31 (Revenue 978.4m / 747.4m)
TATA: -0.06 (NI 105.8m - CFO 189.5m) / TA 1.49b)
Beneish M = -3.05 (Cap -4..+1) = AA

What is the price of ANIP shares?

As of September 04, 2026, the stock is trading at USD 71.99 with a total of 337,841 shares traded. Over the past week, the price has changed by -2.07%, over one month by -10.08%, over three months by -4.31% and over the past year by -24.16%.

Current recommended Stop Loss: 68.90 (which is 4.3% or 1.3 ATR below the current price).

Is ANIP a buy, sell or hold?

ANI Pharmaceuticals has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ANIP.

StrongBuy: 3
Buy: 2
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the ANIP price?

Analysts Target Price	108.4	50.5%

ANI Pharmaceuticals (ANIP) - Fundamental Data Overview as of 29 August 2026

Market Cap USD = 1.69b (1.69b USD * 1.0 USD.USD)
P/E Trailing = 16.0153
P/E Forward = 8.4531
P/S = 1.7259
P/B = 2.8667
P/EG = 1.06
Revenue TTM = 978.4m USD
EBIT TTM = 170.0m USD
EBITDA TTM = 255.8m USD
Long Term Debt = 589.2m USD (from longTermDebt, last quarter)
Short Term Debt = 21.3m USD (from shortTermDebt, last quarter)
Debt = 610.5m USD (corrected: LT Debt 589.2m + ST Debt 21.3m)
Net Debt = 234.6m USD (calculated: Debt 610.5m - CCE 375.9m)
Enterprise Value = 1.92b USD (1.69b + Debt 610.5m - CCE 375.9m)
Interest Coverage Ratio = 6.20 (Ebit TTM 170.0m / Interest Expense TTM 27.4m)
EV/FCF = 12.06x (Enterprise Value 1.92b / FCF TTM 159.4m)
FCF Yield = 8.29% (FCF TTM 159.4m / Enterprise Value 1.92b)
FCF Margin = 16.30% (FCF TTM 159.4m / Revenue TTM 978.4m)
Net Margin = 10.82% (Net Income TTM 105.8m / Revenue TTM 978.4m)
Gross Margin = 65.23% ((Revenue TTM 978.4m - Cost of Revenue TTM 340.2m) / Revenue TTM)
Gross Margin QoQ = 62.35% (prev 51.78%)
Tobins Q-Ratio = 1.29 (Enterprise Value 1.92b / Total Assets 1.49b)
Interest Expense / Debt = 4.49% (Interest Expense 27.4m / Debt 610.5m)
Taxrate = 24.04% (34.3m / 142.6m)
NOPAT = 129.1m (EBIT 170.0m * (1 - 24.04%))
Current Ratio = 2.91 (Total Current Assets 825.4m / Total Current Liabilities 283.7m)
Debt / Equity = 1.02 (Debt 610.5m / totalStockholderEquity, last quarter 597.2m)
Debt / EBITDA = 0.92 (Net Debt 234.6m / EBITDA 255.8m)
Debt / FCF = 1.47 (Net Debt 234.6m / FCF TTM 159.4m)
Total Stockholder Equity = 551.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.46% (Net Income 105.8m / Total Assets 1.49b)
RoE = 19.19% (Net Income TTM 105.8m / Total Stockholder Equity 551.5m)
RoCE = 14.91% (EBIT 170.0m / Capital Employed (Equity 551.5m + L.T.Debt 589.2m))
RoIC = 10.92% (NOPAT 129.1m / Invested Capital 1.18b)
WACC = 5.25% (E(1.69b)/V(2.30b) * Re(5.91%) + D(610.5m)/V(2.30b) * Rd(4.49%) * (1-Tc(0.24)))
Discount Rate = 5.91% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.44 | Cagr: 5.51%
[DCF] Terminal Value 77.97% ; FCFF base≈137.7m ; Y1≈157.9m ; Y5≈232.3m
[DCF] Fair Price = 142.0 (EV 3.50b - Net Debt 234.6m = Equity 3.26b / Shares 23.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 60.15 | EPS CAGR: 22.95% | SUE: 0.33 | # QB: 0
Revenue Correlation: 99.36 | Revenue CAGR: 34.49% | SUE: 0.77 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.16 | Chg30d=-13.71% | Revisions=-40% | Analysts=8
EPS current Year (2026-12-31): EPS=9.28 | Chg30d=-1.45% | Revisions=+0% | GrowthEPS=+17.7% | GrowthRev=+24.9%
EPS next Year (2027-12-31): EPS=10.44 | Chg30d=-2.95% | Revisions=+17% | GrowthEPS=+12.5% | GrowthRev=+11.5%
[Analyst] Revisions Ratio: -10% (up=3, down=4)